PMS43 - A Cost-Effectiveness Analysis of Abatacept, Tocilizumab, And Tnf-Inhibitor Compared With Rituximab As A Second-Line Therapy For Treatment of Rheumatoid Arthritis.
Saved in:
| Title: | PMS43 - A Cost-Effectiveness Analysis of Abatacept, Tocilizumab, And Tnf-Inhibitor Compared With Rituximab As A Second-Line Therapy For Treatment of Rheumatoid Arthritis. |
|---|---|
| Authors: | Huoponen, S1, Aaltonen, KJ1, Joensuu, JT1, Rutanen, J2, Relas, H3, Taimen, K4, Puolakka, K5, Sokka, T6, Nordström, D3, Blom, M1 |
| Source: | Value in Health. Nov/Dec2016, Vol. 19 Issue 7, pA538-A538. 1p. |
| Database: | Academic Search Ultimate |
| ISSN: | 10983015 |
|---|---|
| DOI: | 10.1016/j.jval.2016.09.1110 |
